从精准诊断到精准化疗——精准医疗时代新型肿瘤标志分子研究进展

doi:10.3969/j.issn.1673-8640.2022.04.002

检验医学 ›› 2022, Vol. 37 ›› Issue (4): 309-312.DOI: 10.3969/j.issn.1673-8640.2022.04.002

• 新型肿瘤标志分子研究专题 • 上一篇下一篇

从精准诊断到精准化疗——精准医疗时代新型肿瘤标志分子研究进展

高锋

上海交通大学附属第六人民医院检验科,上海 200233

收稿日期:2021-11-29 修回日期:2022-03-01 出版日期:2022-04-30 发布日期:2022-06-07
作者简介:高锋,男,1962年生,博士,研究员,主要从事肿瘤转移及耐药机制研究。
基金资助:
国家自然科学基金资助项目(81872357);国家自然科学基金资助项目(82073199)

Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy

GAO Feng

Department of Clinical Laboratory,Shanghai Jiao Tong University Affiliated Sixth People's Hospital,Shanghai 200233,China

Received:2021-11-29 Revised:2022-03-01 Online:2022-04-30 Published:2022-06-07

摘要/Abstract

摘要：

恶性肿瘤是威胁人类健康的主要疾病。目前,中国的肿瘤诊疗水平与欧美发达国家相比,仍存在较大的差距。要实现健康中国目标,肿瘤的早期诊断和精准综合诊疗是关键。然而,没有精准诊断,就没有精准治疗。精准诊断的基础是对肿瘤特征的深入认识。近年来,新的肿瘤分子特征的发现正改变着肿瘤诊疗的思路与策略,为肿瘤诊疗带来了新的机遇和挑战。新型肿瘤标志分子正逐渐在肿瘤辅助诊断、疗效预测、监测复发和转移,及预后判断中发挥越来越重要的作用。

关键词: 新型肿瘤标志分子, 精准诊断, 精准化疗, 表观遗传可塑, 肿瘤异质性

Abstract:

Malignant tumors have evolved into a severe hazard to human health. Between China's tumor diagnosis and treatment and those of Europe,America and other developed countries,there is still a significant disparity. Early determination and accurate comprehensive diagnosis and treatment are essential for achieving the aim of a healthy China. However,there can be no proper therapy without an accurate diagnosis. Accurate diagnosis is based on a thorough understanding of tumor features and their evolution. The discovery of new tumor molecular features has changed tumor diagnostic and treatment concepts and strategies in the recent years,presenting a new opportunity and challenge in the area of tumor diagnosis and therapy. New tumor marker molecules are increasingly becoming more essential in clinical tumor diagnosis,recurrence,metastasis monitoring and prognosis.

Key words: New tumor marker molecule, Accurate diagnosis, Precision chemotherapy, Epigenetic plasticity, Cancer heterogeneity

中图分类号:

R393

高锋. 从精准诊断到精准化疗——精准医疗时代新型肿瘤标志分子研究进展[J]. 检验医学, 2022, 37(4): 309-312.

GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy[J]. Laboratory Medicine, 2022, 37(4): 309-312.

参考文献 30

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI URL
[2]	BAHCALL O. Precision medicine[J]. Nature, 2015, 526(7573):335. DOI URL
[3]	BIANKIN A V, PIANTADOSI S, HOLLINGSWORTH S J. Patient-centric trials for therapeutic development in precision oncology[J]. Nature, 2015, 526(7573):361-370. DOI URL
[4]	FLAVAHAN W A, GASKELL E, BERNSTEIN B E. Epigenetic plasticity and the hallmarks of cancer[J]. Science, 2017, 357(6348):eaal2380.
[5]	GREAVES M, MALEY C C. Clonal evolution in cancer[J]. Nature, 2012, 481(7381):306-313. DOI URL
[6]	MEACHAM C E, MORRISON S J. Tumour heterogeneity and cancer cell plasticity[J]. Nature, 2013, 501(7467):328-337. DOI URL
[7]	DAGOGO-JACK I, SHAW A T. Tumour heterogeneity and resistance to cancer therapies[J]. Nat Rev Clin Oncol, 2018, 15(2):81-94. DOI URL
[8]	MCGRANAHAN N, SWANTON C. Clonal heterogeneity and tumor evolution:past,present,and the future[J]. Cell, 2017, 168(4):613-628. DOI URL
[9]	MCGRANAHAN N, SWANTON C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution[J]. Cancer Cell, 2015, 27(1):15-26. DOI URL
[10]	TSIMBERIDOU A M, FOUNTZILAS E, NIKANJAM M, et al. Review of precision cancer medicine:evolution of the treatment paradigm[J]. Cancer Treat Rev, 2020, 86:102019.
[11]	KEEGAN N M, GLEESON J P, HENNESSY B T, et al. PI3K inhibition to overcome endocrine resistance in breast cancer[J]. Expert Opin Investig Drugs, 2018, 27(1):1-15. DOI URL
[12]	ANDRÉ F, CIRUELOS E, RUBOVSZKY G, et al. Alpelisib for PIK3CA-mutated,hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2019, 380(20):1929-1940. DOI URL
[13]	DAWSON M A, KOUZARIDES T. Cancer epigenetics:from mechanism to therapy[J]. Cell, 2012, 150(1):12-27. DOI URL
[14]	VALENCIA A M, KADOCH C. Chromatin regulatory mechanisms and therapeutic opportunities in cancer[J]. Nat Cell Biol, 2019, 21(2):152-161. DOI URL
[15]	KOCH A, JOOSTEN S C, FENG Z, et al. Analysis of DNA methylation in cancer:location revisited[J]. Nat Rev Clin Oncol, 2018, 15(7):459-466. DOI URL
[16]	OKUGAWA Y, GRADY W M, GOEL A. Epigenetic alterations in colorectal cancer:emerging biomarkers[J]. Gastroenterology, 2015, 149(5):1204-1225.e12. DOI URL
[17]	GRADY W M, YU M, MARKOWITZ S D. Epigenetic alterations in the gastrointestinal tract:current and emerging use for biomarkers of cancer[J]. Gastroenterology, 2021, 160(3):690-709. DOI URL
[18]	GYÖRFFY B, BOTTAI G, FLEISCHER T, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes[J]. Int J Cancer, 2016, 138(1):87-97. DOI URL
[19]	SUIJKERBUIJK K P M, VAN DIEST P J, VAN DER WALL E. Improving early breast cancer detection:focus on methylation[J]. Ann Oncol, 2011, 22(1):24-29. DOI URL
[20]	HAO X, LUO H, KRAWCZYK M, et al. DNA methylation markers for diagnosis and prognosis of common cancers[J]. Proc Natl Acad Sci U S A, 2017, 114(28):7414-7419. DOI URL
[21]	TANG Q, CHENG J, CAO X, et al. Blood-based DNA methylation as biomarker for breast cancer:a systematic review[J]. Clin Epigenetics, 2016, 8:115. DOI URL
[22]	ALLOUCHERY V, PERDRIX A, CALBRIX C, et al. Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients[J]. Sci Rep, 2021, 11(1):24041. DOI URL
[23]	HUANG A, GUO D Z, WANG Y P, et al. Plasma microRNA panel predicts early tumor recurrence in patients with hepatocellular carcinoma after liver transplantation[J]. J Cancer, 2021, 12(23):7190-7200. DOI URL
[24]	DEBEN C, DESCHOOLMEESTER V, LARDON F, et al. TP53 and MDM2 genetic alterations in non-small cell lung cancer:evaluating their prognostic and predictive value[J]. Crit Rev Oncol Hematol, 2016, 99:63-73. DOI URL
[25]	BURGESS A, CHIA K M, HAUPT S, et al. Clinical overview of MDM2/X-targeted therapies[J]. Front Oncol, 2016, 6:7.
[26]	DUFFY M J, SYNNOTT N C, MCGOWAN P M, et al. P53 as a target for the treatment of cancer[J]. Cancer Treat Rev, 2014, 40(10):1153-1160. DOI URL
[27]	SOUID S, AISSAOUI D, SRAIRI-ABID N, et al. Trabectedin(Yondelis^®) as a therapeutic option in gynecological cancers:a focus on its mechanisms of action,clinical activity and genomic predictors of drug response[J]. Curr Drug Targets, 2020, 21(10):996-1007. DOI URL
[28]	CHEN J, YIN J, LI X, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients[J]. Int J Mol Sci, 2014, 15(11):21011-21027. DOI URL
[29]	DULDULAO M P, LEE W, NELSON R A, et al. Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer[J]. Cancer, 2013, 119(5):1106-1112. DOI URL
[30]	LIU J, LUO J, WANG Y, et al. Predictive potential role of glutathione S-transferases polymorphisms on prognosis of breast cancer[J]. Int J Clin Exp Pathol, 2014, 7(12):8935-8940.

从精准诊断到精准化疗——精准医疗时代新型肿瘤标志分子研究进展

Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

[1]	杨玉强, 全晓丽, 王刘玉, 鲜文峰, 杨红. 骨肉瘤组织RRBP1表达及其对细胞生物学特征的影响[J]. 检验医学, 2023, 38(9): 842-848.
[2]	王杨淑怡, 叶威, 林志豪, 黄约诺, 方涛, 董晓亭. 肺腺癌焦亡相关特征模型的构建和验证[J]. 检验医学, 2023, 38(9): 833-841.
[3]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[4]	王蓉, 邢连翔, 黄克亮, 李欣. miR-374靶向下调TRIM35表达可促进乳腺癌细胞增殖和侵袭[J]. 检验医学, 2023, 38(9): 812-817.
[5]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[6]	张旭明, 尹伟明, 高婧. 深圳市宝安地区妊娠期甲状腺功能减退患者UGT1A1基因多态性与妊娠期合并症和不良妊娠结局的关系[J]. 检验医学, 2023, 38(7): 665-668.
[7]	潘信, 吕颖, 李阳, 李荣国. miR-24-3p靶向CHD5影响甲状腺癌细胞迁移能力、侵袭能力和放射敏感性[J]. 检验医学, 2023, 38(7): 640-646.
[8]	陈文举, 周勇, 徐佳佳, 王攀. 血清外泌体miR-23b-3p和miR-4429诊断HCC的价值[J]. 检验医学, 2023, 38(7): 624-628.
[9]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[10]	张银龙, 杨红. 骨肉瘤组织长链非编码RNA ZFAS1的表达及其临床意义[J]. 检验医学, 2023, 38(3): 240-244.
[11]	李牧, 龚东亮, 徐黎明, 彭荣. XPC rs2228000位点多态性与乳腺癌发病的关系[J]. 检验医学, 2023, 38(3): 235-239.
[12]	吴亚婷, 李卓林, 雷艳, 贾如雪, 张胜行, 王水良. 尿液中miRNA作为常见恶性肿瘤生物标志物研究进展[J]. 检验医学, 2023, 38(1): 94-99.
[13]	吴文萍, 徐林娟, 王佳亨, 张娜娜. PBK/TOPK表达与老年急性髓系白血病患者治疗反应和生存预后的关联分析[J]. 检验医学, 2022, 37(11): 1017-1022.
[14]	王鼎, 李福刚, 罗旺, 陈华剑, 张珂, 谢国明. 长链醇类和油类物质洗涤液在磁珠法DNA和RNA共提取中的应用[J]. 检验医学, 2022, 37(11): 1079-1083.
[15]	周焕, 唐颖, 杜翠萍, 杨扬, 冯会杰, 邱淼欣, 闫佩毅, 蔡骁垚, 金姝. lncRNA SNHG5对人类下咽癌细胞转录组学的影响及意义[J]. 检验医学, 2022, 37(3): 281-287.